Enanta Pharmaceuticals announce PEARL-III study results in patients with Chronic Hepatitis C

04-03-2014 Business Wire HealthComments (0)

Enanta PharmaceuticalsPharmaceuticalUSA

Enanta Pharmaceuticals (NASDAQ:ENTA) today announced that detailed results from the PEARL-III study were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III is one of the six phase 3 registrational studies conducted by AbbVie for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection using a reg

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top